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The relationship between Aldosterone level and various LV 
conditions in patients with End-stage renal disease 
 
 
Abstract 
Background: Aldosterone has been assumed to be implicated in left ventricular 
hypertrophy (LVH). Preventing the progression of LVH in the early period of end-stage 
renal disease (ESRD) can increase patient survival. In this study, therefore, we analyzed 
the relationship between aldosterone level and LVH in ESRD patients who underwent 
hemodialysis at Fatemeh Zahra Hospital and Imam Khomeini Hospital in Sari, Iran from 
2016 to 2017. 
Methods: This research is a case-control study involving 69 patients, divided into the case 
group (n=52, exhibiting LVH) and the control group (n=17, no ventricular hypertrophy 
observed in the echocardiography). The relationship between the patients’ serum 
aldosterone levels and LVH was evaluated on the basis of relative wall thickness (RWT). 
Results: Among the patients, 20.3% had normal cardiac conditions, 53.6% eccentric 
hypertrophy (EH), 4.3% exhibited concentric remodeling (CR), and 21.7% had concentric 
hypertrophy (CH). In other words, 24.6% of the patients belonged to the control group, 
and 75.4% belonged to the case group. The results indicated a significant difference 
(P=0.006) in average aldosterone levels between the case (165.11±80.8) and control 
(115.76±72.47) groups and a significant difference in aldosterone levels among the four 
subgroups (P=0.03), with the levels of the CH group being higher than those of the EH 
group. 
Conclusion: Based on the results of the study, a significant relationship exists between 
plasma aldosterone level and LVH in ESRD patients. Serum aldosterone level is therefore 
a predictor of LVH. 
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Cardiovascular diseases are major causes of mortality among patients with end-stage 
renal disease (ESRD) (1, 2), who are highly at risk of developing left ventricular 
hypertrophy (LVH) (3, 4). Cardiovascular disease includes coronary artery diseases (CAD) 
such as angina and myocardial infarction (commonly known as a heart attack). Most 
cardiovascular diseases affect older adults. In the United States, 11% of people between 20 
and 40 have CVD, while 37% between 40 and 60, 71% of people between 60 and 80, and 
85% of people over 80 have CVD (5). LVH is a condition in which muscular hypertrophy 
occurs as a result of the difficulty of the heart’s left ventricle in pumping blood. LVH 
causes systolic and diastolic dysfunction, reduces blood supply in coronary arteries, and 
eventually gives rise to side effects such as ischemia, myocardial infarction, heart failure, 
and sudden death. 
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The physiological factors responsible for LVH are 
isometric exercise, pregnancy, old age, obesity, and salt 
intake; the pathological factors implicated in the disease are 
relevant to hypertension (HTN), aortic stenosis (AS), aortic 
insufficiency, hypertrophic cardiomyopathy, and other 
cardiomyopathies (6). The specific incidence rate of LVH 
among patients with ESRD is 68% to 89%, and the disease 
often occurs in progressive form (3, 7). The prevention of 
LVH can improve the survival of ESRD patients. For 
example, a 10% reduction in LVH results in a 28% decrease 
in the risk of cardiac mortality among patients on dialysis (8, 
9).  LVH is also a powerful predictor of mortality and an 
independent risk factor for patients with chronic kidney 
disease (CKD) (10-12), which involves a range of 
pathological mechanisms concerned with abnormal kidney 
function and progressive reduction in glomerular filtration. 
CKD is most commonly caused by diabetic nephropathy, 
diabetes mellitus type 2, and hypertensive nephropathy. Its 
diagnosis can be considerably facilitated by laboratory tests, 
imaging studies, frequent measurements of plasma urea and 
creatinine concentrations, and renal biopsy. In imaging 
studies, observations of metabolic bone disease with 
hyperphosphatemia, hypoxia, increased levels of parathyroid 
hormone (PTH) and radiological disorders, normocytic and 
normochromic anemia, and reduced kidney size (<8.5 cm) 
strongly favor CKD (6). 
ESRD is the final stage of CKD, and the genesis of 
hypertrophy in the former may be caused by several factors, 
such as HTN (13), increased PTH levels (14), and the renin–
angiotensin–aldosterone system (11). Clinical evidence 
indicated that aldosterone plays a pathologic role in cardiac 
hypertrophy—a role that appears to be independent of its 
effect on blood pressure (11, 15-17). Aldosterone is a 
mineralocorticoid that is produced in adrenal cortical 
glomeruli and plays a substantial role in sodium and water 
reabsorption as well as potassium secretion (6). Primary 
aldosteronism appears to increase the incidence of LVH, as 
evidenced by the higher number of LVH cases in patients 
with primary aldosteronism than in subjects with 
renovascular HTN (18). Ritz and Amman found that 
comparing with patients who have preserved renal function, 
ESRD patients with LVH exhibit myocyte hypertrophy, loss 
of myocardial capillaries, increased interstitial fibrosis, and 
reduced capillary-to-myocyte ratio (19). The morphological 
findings of in vitro and in vivo studies showed that increased 
levels of aldosterone affect non-myocyte cells (endothelial 
and cardiac fibroblasts) and accordingly result in collagen 
accumulation and myocardial fibrosis, which can contribute 
to LVH pathogenesis (17). Some studies found that plasma 
aldosterone levels are related to concentric LVH (17, 20). 
During treatment of concentric LVH in certain studies, for 
example, aldosterone inhibitors reduced left ventricular mass 
index (LVMI) in patients with HTN but did not eliminate 
LVH (21, 22). Other studies suggested that in ESRD patients 
on dialysis, aldosterone inhibition causes LVH to regress 
(23). In research involving ESRD patients of different races, 
however, no relationship was observed between aldosterone 
level and LVH (24, 25). As seen in the discussion above, the 
role of aldosterone in hypertrophy incidence is known, with 
studies providing contradictory results in this regard (26-28). 
The necessity of preventing LVH and implementing timely 
intervention during the early stages of ESRD (8, 16, 22) 
highlights the importance of exploring whether decreased 
aldosterone levels in ESRD patients reduce the incidence of 
LVH. Accordingly, the present research was conducted with 
the aim of analyzing the relationship between aldosterone 
level and LVH in ESRD patients undergoing dialysis at 
Imam Khomeini Hospital and Fatemeh Zahra Hospital in 
Sari, Iran from 2016 to 2017. 
 
 
Methods 
Study design and patients: This case-control study 
involved 69 ESRD patients admitted into Fatemeh Zahra 
Hospital and Imam Khomeini Hospital from 2016 to 2017. 
Sixty nine participants were selected via census sampling, 52 
patients were in the case group who had LVH, and 17 
patients in the control group with no hypertrophy. Data were 
collected from the field using a questionnaire validated by 
six cardiology specialists. The inclusion criteria were as 
follows: being on dialysis twice a week for at least three 
months, having an ejection fraction (EF) greater than 40%, 
and having a blood pressure lower than 160/100. The 
exclusion criteria were: having a blood pressure greater than 
160/100; the presence of coronary artery disease, cardiac 
valve disease, atrial fibrillation, congestive heart failure, 
diabetes mellitus, and having taken angiotensin-converting 
enzyme inhibitors (ACEIs) and angiotensin-receptor 
blockers (ARBs) during the past two weeks. After the 
patients were informed of the necessity of the study and 
sampling, written consent was obtained from them. All the 
eligible patients underwent B-Mode 2D echocardiography 
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supervised by a cardiologist and were then divided into the 
case group, composed of patients exhibiting LVH, and the 
control group, consisting of patients whose echocardiograms 
reflected no LVH. 
Measures:  Intervening factors such as potassium and blood 
glucose levels, blood pressure, period of hemodialysis, age, 
and sex were homogenized. In both groups, biochemical 
factors such as plasma aldosterone, sodium, potassium, 
creatinine, urea, triglyceride, high-density lipoprotein, and 
low-density lipoprotein levels were measured. The systolic 
and diastolic blood pressure and body mass index of the 
patients were recorded in the questionnaire. Enzyme-linked 
immunosorbent assay (IBL, Germany) was conducted to 
measure the aldosterone levels of the patients. Two weeks 
after the primary examination, a blood glucose test to 
exclude diabetic patients from studying and matching 
patients and echocardiography were conducted. In 
hypertensive patients, the ACEI and ARB drugs were 
substituted with other medications for two weeks. This issue 
has been informed to patients. 
Fasting blood sugar was measured after 20 minutes of 
rest in a supine position. The LV diastolic dimension 
(LVDd), interventricular septal thickness (IVST), posterior 
wall thickness (PWT), and LV ejection fraction (LVEF) 
were measured in the parasternal long axis view using 2D 
echocardiography (Philips). The body area for LV mass 
measurement was calculated using the Devereaux formula, 
and the value was recorded as the LV mass index. The 
patients having an LVMI greater than 125 g/m
2
 were placed 
in the case group. Relative wall thickness (RWT) was 
calculated by multiplying the PWT value by 2 and then 
dividing the result by the LVDd value. Values higher than 
0.44 were considered to reflect increased RWT. On the basis 
of the geometric values of the left ventricle, the patients were 
further subdivided into four groups, namely, the normal (N) 
group, who exhibited normal RWT and LVMI; the 
concentric remodeling (CR) group, who presented normal 
LVMI and increased RWT; the eccentric hypertrophy (EH) 
group, comprising patients with increased LVMI and normal 
RWT; and the concentric hypertrophy (CH) group, 
consisting of patients with increased LVMI and RWT. The 
patients’ blood pressure and heartbeat were measured in a 
sitting position (after 5 minutes of rest). 
Ethical considerations: The study was conducted in 
accordance with the principles of the Declaration of Helsinki 
and informed consent was obtained from all patients. 
Statistical methods: To evaluate whether the data were 
normally distributed, the Kolmogorov–Smirnov test was 
performed. Given the non-normal distribution, non-
parametric tests were used to analyze the data. All the data 
were analyzed using the Statistical Package for the Social 
Sciences Version 22. Kruskal–Wallis and Mann–Whitney 
tests were carried out to determine the differences in LVH 
levels between the groups. A p-value less than 0.05 was 
considered statistically significant. 
 
 
Results 
The patients’ ages ranged from 35 to 91 years, with the 
average being 62±13.86. Out of the 69 patients, 34 (49.3%) 
were women and 35 (50.7%) were men. The total average 
sodium and potassium levels and systolic and diastolic blood 
pressure were 142.29±2.98 and 4.54±0.72 and 126.53±10.42 
and 77.20±10.17, respectively. These values were 
homogenized in the two groups (p>0.05, table 1). 
 
Table 1: Frequency distribution of clinical variables  
Variables  Control Case Total P-
value Mean±SD Mean±SD Mean±SD 
Age 59.31±15.30 62.62±13.38 61.78±13.86 0.351 
Sodium 141.36±2.77 142.6±3.01 142.29±2.98 0.783 
Potassium 4.5±0.63 4.56±0.75 4.54±0.72 0.622 
SBP 123.68±10.65 127.50±10.26 126.53±10.42 0.311 
DBP 76.84±9.45 77.32±10.48 77.20±10.17 0.636 
 
Out of the 69 patients, 14 (20.3%) belonged to the N 
group, 37 (53.6%) the EH group, 3 (4.3%) the CR group, and 
15 (21.7%) belonged to the CH group (table 2). 
 
Table 2: Frequency Distribution Based on Geometric 
Values of the Left Ventricle 
Group Frequency 
(percent) 
Frequency 
among women 
Frequency 
among men 
N 14 (20.3%) 9 5 
EH 37 (53.6%) 16 21 
CR 3 (4.3%) 3 0 
CH 15 (21.7%) 6 9 
Total 69 (100%) 34 35 
(N) Normal group= normal values of RWT and LVMI, (CR) concentric 
remodeling group= normal LVMI and increased RWT, (EH) Eccentric 
hypertrophy group= increased LVMI and normal RWT; (CH) concentric 
hypertrophy group= increased LVMI and increased RWT 
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 With respect to primary grouping, 17 patients (24.6%) 
belonged to the control group, whose subgroups were the N 
and CR groups; 52 (75.4%) belonged to the case group, 
whose subgroups comprised the CH and EH patients. The 
results of the Mann–Whitney test indicated a significant 
difference in aldosterone levels between the case group 
(165.11±80.8) and the controls (115.76±72.47, P=0.006). 
Table 3 shows the average aldosterone level of each of the 
four subgroups. The average aldosterone level of all the 69 
participants was 152.95±81.25. The results of the Kruskal–
Wallis test indicated a significant statistical difference in 
aldosterone levels among the four subgroups (P=0.032). 
 
Table 3: Average aldosterone levels of the subgroups 
Groups Aldosterone Level P-value 
Mean±SD 
N 116.14±72.21 
*
P=0.032 
EH 154.21±76.38 
CR 114±90 
CH 192±87.9 
Total 152.95±81.25  
(N) Normal group= normal values of RWT and LVMI, (CR) concentric 
remodeling group= normal LVMI and increased RWT, (EH) Eccentric 
hypertrophy group= increased LVMI and normal RWT; (CH) concentric 
hypertrophy group= increased LVMI and increased RWT 
*Kruskalwallis test 
 
 
Discussion 
Patients with CKD exhibit abnormally high aldosterone 
levels (29). Although the relationship between LV mass and 
aldosterone levels in hypertensive and diabetic patients was 
well clarified, this issue has not been examined with respect 
to CKD patients, especially those undergoing dialysis (11). 
To address this gap, this study was conducted with the aim 
of evaluating the relationship between aldosterone level and 
LVH in ESRD patients on dialysis. The findings indicated a 
significant relationship between high aldosterone levels and 
increased hypertrophy of the left ventricle. This outcome, in 
turn, can increase the mortality of ESRD patients on dialysis, 
the mortality resulting from cerebrovascular diseases, and 
the mortality and morbidity of cardiovascular diseases (30-
33). Other studies presented similar results (11, 15, 24, 34). 
Bomback et al. (29), for instance, found that the average 
aldosterone levels of ESRD patients were higher than those 
of healthy individuals (26.7 and 12.4 mg/dl, respectively). 
The difference was significant. In the current work, the 
aldosterone levels of the case and control groups were 
165.11±80.8 and 115.76±72.47, respectively, also exhibiting 
a significant difference. 
The mean aldosterone level in the whole patient is 
152.95±81.25 and the normal level in aldosterone is given in 
table 3. In our study, about 75% of the patients suffered from 
LVH. In this proportion of patients, CH was more 
significantly related to aldosterone level than EH. Mule et al. 
(2015), who examined the concentration of plasma 
aldosterone and its relationship with LVM in CKD 
hypertensive patients, indicated that LVM, RWT, and 
plasma aldosterone concentration increased in these 
patients—conditions that are associated with the early stages 
of renal failure. The authors also reported a close 
relationship between plasma aldosterone concentration and 
concentric LVH, compared with patients with eccentric 
LVH, those suffering from eccentric LVH exhibited lower 
plasma aldosterone concentrations (22). Nakahar et al. (20) 
investigated 57 patients with CH and EH and found a 
significant relationship among plasma aldosterone level, 
LVMI, and the wall thickness of the left ventricle. This result 
was particularly prominent in the concentric group, 
consistent with our findings. Taken together, these findings 
indicated that eccentric LVH patients, who are mostly people 
with volume overload, exhibit increased LVMI but normal 
RWT. 
 In patients with concentric LVH, who are mostly people 
afflicted with blood pressure or pressure overload, LVMI 
and RWT increase; in the latter type of patients, blood 
aldosterone levels also significantly increased. In the studies 
conducted by Adebiyi et al (25), El-Gharbawy et al. (35), 
and Vasan (28), however, no significant relationship was 
found between LVMI and plasma aldosterone. The 
difference in findings can be attributed to type of population 
studied. 
In conclusion, on the whole, the results and their 
comparison with those of other studies indicated a significant 
relationship between plasma aldosterone level and LVH in 
ESRD patients. Therefore, monitoring serum aldosterone 
levels can help predict the occurrence of LVH. 
Power and limitation study 
This study can be used as a marker for predicting 
hypertrophy. But regarding the limitation of the study, 
participants were often excluded from the study due to 
underlying illness and the use of ARB, ACE medications. 
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